Maravai Lifesciences Holdings, Inc. Class A MRVI 深 沪
等待开盘 05-20 09:30:00 美东时间
4.22
+0.140
+3.43%
华盛通- 最 高4.28
- 今 开4.05
- 成交量 219.61万股
- 最 低 4.00
- 昨 收 4.08
- 总市值 10.90亿
- 52周最高 4.995
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 1.99
- 委 比 -46.54%
- 总股本 2.58亿
- 历史最高 63.55
- 量 比 1.09
- 振 幅 6.86%
- 历史最低 1.665
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
电话会总结 ｜ Maravai(MRVI)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Maravai业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收6,580万美元，同比增长41% - 基础业务营收（剔除COVID相关CleanCap收入）同比增长10% - TriLink业务营收同比增长65%，基础业务增长15% - Cygnus业务营收同比增长略超1% **盈利能力：** - 调整后毛利率65.3%，受益于产品组合优化和成本控制 - 调整后EBITDA为2,030万美元，同比改善超过3,000万美元 - GAAP净亏损（扣除非控制性权益前）640万美元，去年同期为5,
05-10 12:01
Maravai LifeSciences Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance above estimates.
Maravai LifeSciences Holdings shares are trading higher after the company repor...
05-08 05:22
Maravai LifeSciences Raises FY2026 Sales Guidance from $200.000M-$210.000M to $205.000M-$215.000M vs $204.933M Est
Maravai LifeSciences (NASDAQ:MRVI) raises FY2026 sales outlook from $200.000 million-$210.000 million to $205.000 million-$215.000 million vs $204.933 million estimate.
05-08 04:03
Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment
Royal Philips has announced proposed appointments and re-appointments to its Supervisory Board. John DeFord, an industry leader with extensive experience in medical devices, has been nominated as a new member. Paul Stoffels, Herna Verhagen, and Sanjay Poonen have been proposed for re-appointment due to their ongoing contributions and expertise. Marc Harrison will step down after completing his second term. Additionally, Roy Jakobs has been re-pro...
03-23 08:30
Maravai Lifesciences Charts Early Turnaround in 2025
Maravai Lifesciences Holdings, Inc. (($MRVI)) has held its Q4 earnings call. Re...
03-01 08:26
Maravai LifeSciences Holdings shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance with its midpoint above estimates.
Maravai LifeSciences Holdings shares are trading higher after the company repor...
02-26 06:02
Maravai LifeSciences Sees FY2026 Sales $200.000M-$210.000M vs $203.430M Est
Maravai LifeSciences (NASDAQ:MRVI) sees FY2026 sales of $200.000 million-$210.000 million vs $203.430 million analyst estimate.
02-26 05:08
Maravai LifeSciences Q4 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $49.866M Beat $49.047M Estimate
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 43.66 percent. This is a 33.33 percent increase over losses of $(0.06) per share
02-26 05:07
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
